MDV 4463

Drug Profile

MDV 4463

Alternative Names: MDV4463

Latest Information Update: 30 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Medivation
  • Class Small molecules
  • Mechanism of Action Sterol regulatory element binding protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis

Most Recent Events

  • 28 Sep 2016 Medivation has been acquired by Pfizer
  • 26 Feb 2016 Phase-I clinical trials in Non-alcoholic steatohepatitis (In volunteers) in USA (unspecified route)
  • 26 Feb 2016 Preclinical trials in Non-alcoholic steatohepatitis in USA (unspecified route) before February 2016
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top